Quick Answer
EVO ICL surgery carries real but low risks in properly screened candidates. The most clinically significant risks include elevated intraocular pressure (early postoperative), anterior subcapsular cataract (rare with the EVO design), halos and glare (common but usually temporary), and lens rotation in toric cases. Serious vision-threatening complications such as infection are very rare. Overall, the CIRCA clinical trial reported a safety index greater than 1.0, meaning most patients see better without glasses after surgery than they did with glasses before.
Detailed Explanation
Understanding the risk profile of EVO ICL surgery is essential for any patient making an informed consent decision. The risks fall into several categories: early postoperative, related to the lens itself, and procedural.
Early postoperative risks:
1. Elevated intraocular pressure (IOP spike)
This is the most important acute postoperative risk. In the early hours after EVO ICL surgery, residual viscoelastic substance (used to protect the eye during surgery) can temporarily obstruct aqueous outflow and raise IOP. If not detected and treated, elevated IOP can damage the optic nerve.
The EVO ICL’s KS-AquaPORT design significantly reduced the rate of IOP elevation compared to older ICL models by allowing more natural aqueous flow. However, IOP elevation can still occur and is the reason the Day 1 post-operative appointment is mandatory.
IOP-related risk management:
- IOP is checked before the patient leaves the surgical center
- Oral acetazolamide or topical IOP-lowering drops may be given prophylactically in high-risk patients
- If significant IOP elevation is detected at Day 1, prompt treatment is initiated
2. Infection (endophthalmitis)
Intraocular infection is among the most feared complications of any eye surgery. In EVO ICL surgery, the incidence of endophthalmitis is extremely low — comparable to or lower than modern cataract surgery rates, which are estimated at approximately 0.02 to 0.05%. Strict sterile surgical technique and the mandatory postoperative antibiotic drop course are the primary preventive measures.
Lens-related risks:
3. Anterior subcapsular cataract (ASC)
This was a documented complication of older ICL models, occurring when a poorly vaulting lens made contact with the natural crystalline lens and caused focal opacity. The EVO design’s improved vault geometry and KS-AquaPORT system substantially reduced this risk. In the CIRCA trial, the ASC rate with EVO ICL was significantly lower than with prior ICL generations. However, the risk is not zero — patients with very low vault (lens sitting too close to the natural lens) may be at elevated risk.
This risk underscores the importance of accurate preoperative sizing. Correct lens sizing ensures adequate vault between the EVO ICL and the natural lens, minimizing the ASC risk.
4. Elevated IOP due to lens oversizing
If the lens is too large for the posterior chamber, it may exert mechanical pressure on surrounding structures and impair aqueous outflow chronically. This can lead to progressive IOP elevation that requires medical management or lens exchange. Again, accurate sizing is the prevention.
5. Lens decentration or rotation
In spherical lens cases, mild decentration is usually visually insignificant. In Toric EVO ICL cases, rotation of the lens out of the intended axis can reduce or eliminate the astigmatism correction and may cause new refractive error. Clinically significant rotation requiring surgical repositioning occurs in approximately 1 to 2% of toric cases.
For surgeons recognized for excellence in EVO ICL outcomes and complication management, visit the EVO ICL Awards page.
Visual quality risks:
6. Halos and glare
The most commonly reported postoperative visual phenomenon is halos — rings of light around point sources such as streetlights — and glare in bright or high-contrast environments. These are caused by the optical edge of the EVO ICL interacting with the pupil at its boundary.
In most patients, halos and glare are mild, improve over the first 1 to 3 months, and are not clinically significant. In a minority of patients — particularly those with large pupils in low-light conditions and high prescriptions — halos may be more prominent and persistent.
The incidence and severity of halos with EVO ICL is generally comparable to or better than LASIK for patients with equivalent prescriptions.
7. Undercorrection or overcorrection
A small percentage of patients do not achieve target refraction with the primary surgery. Mild residual error (within ±0.5D) is usually clinically acceptable. More significant residual error may warrant lens exchange or supplemental laser treatment. High-volume surgeons achieve target refraction within ±0.5D in approximately 85 to 90% of cases.
Rates from the CIRCA clinical trial:
The following safety outcomes were reported in the FDA CIRCA trial:
- Adverse events requiring lens explantation: less than 1%
- Clinically significant IOP elevation: less than 1%
- Significant endothelial cell loss beyond expected aging: less than 1%
- Visual acuity worse than preoperative best corrected VA: less than 1%
Important Considerations
The risk profile described above assumes a properly screened candidate, an experienced surgeon, accurate preoperative sizing, and rigorous postoperative follow-up. Patients who proceed despite disqualifying factors — insufficient ACD, pre-existing glaucoma, unstable prescription — face substantially higher risk.
The comparison to doing nothing (continuing to wear glasses or contacts) should also be considered honestly. Long-term myopia is itself associated with elevated risk of retinal tears, macular degeneration, and glaucoma — conditions that EVO ICL does not prevent but also does not cause. The risk of EVO ICL is the risk of an elective procedure, weighed against the ongoing risk associated with high myopia itself.
Informed consent before EVO ICL surgery should include a detailed discussion of all risks above, with the surgeon’s specific reported rates for their practice, not just literature averages.
What to Do Next
Ask any surgeon you are considering to discuss their personal complication rates — not just the published literature statistics. Surgeons with high case volume and accurate sizing protocols will have complication rates that compare favorably with published benchmarks.
Review How Do I Find the Best EVO ICL Surgeon? to understand the selection criteria that minimize procedure-related risk.
Related Questions
Is EVO ICL right for my prescription and eye anatomy? See Who Is Not a Good Candidate for EVO ICL? to understand how disqualifying factors connect to elevated risk.
What does recovery look like if everything goes normally? Read What Is the EVO ICL Surgery Recovery Like? for the expected post-surgical course.
Can EVO ICL be removed if a problem develops? Yes — see Can EVO ICL Be Removed? for the removal and exchange process.